– USA, MA – Curie Therapeutics Inc., a biotechnology company focused on developing innovative radiopharmaceutical therapies for oncological diseases, today announced the appointment of Dr. Karen Smith (M.D., Ph.D.) to its Board as Independent Director.
About Dr. Karen Smith
Dr. Smith has overseen numerous trials and regulatory approvals leading to global product launches of small molecules, biologics and devices across oncology and other therapeutic areas. She is an accomplished executive who has led departments within large pharma (Allergan, Astra-Zeneca, Bristol Myers Squibb), and served as CMO or CEO at notable biotech companies (Jazz, ECI, Novosteo). She currently serves on the boards of Antares Pharma, Sangamo Therapeutics and Emyria Ltd. and has helped guide several successful corporate exits through acquisition (Forward Pharma, Sucampo Pharma, Acceleron Pharma).
Dr Smith’s credentials include a B.App.Sc. with a double major in Biotechnology and Haematology; an M.D.; a Ph.D. in oncology molecular genetics; an M.B.A. and a Master of Law (L.L.M.).
About Curie Therapeutics
Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective. Curie’s radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets, to deliver alpha and beta-emitting radionuclide payloads. Curie’s mission is to revolutionize the use of radiomedicines in cancer.
For more information : https://www.curietherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
